Drug-induced long QT syndrome

Area of Science:

• Pharmacology
• Cardiology
• Drug Safety

Background:

• Drug-induced long QT syndrome has evolved from an electrophysiologic curiosity to a critical aspect of drug regulation and development.
• Recognition of rare adverse drug effects significantly impacts the benefit-risk balance in prescribing and drug approval.

Purpose of the Study:

• To outline how understanding the mechanism of drug-induced long QT syndrome aids in risk assessment.
• To discuss models for studying risk and the influence of clinical factors on cardiac repolarization.
• To describe the role of genetic variants in modulating this risk.

Main Methods:

• Review of the central mechanism: block of the cardiac delayed-rectifier potassium current I(Kr).
• Discussion of risk assessment models.
• Analysis of how clinical risk factors modulate cardiac repolarization at the molecular level.
• Description of the role of genetic variants in risk modulation.

Main Results:

• Defining the mechanism (I(Kr) block) is key to understanding and quantifying risk.
• Clinical risk factors and genetic variants significantly influence an individual's susceptibility.
• Established models aid in predicting and managing drug-induced long QT syndrome.

Conclusions:

• Understanding the molecular mechanisms of drug-induced long QT syndrome is crucial for drug safety and regulation.
• Risk stratification requires consideration of both clinical and genetic factors.
• Further research into these mechanisms will improve drug development and patient care.